Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

BACKGROUND: Increased exposure to multitargeted kinase inhibitor sunitinib is associated with improved outcome, emphasizing the importance of maintaining adequate dosing and drug levels. The currently approved schedule (50 mg daily, four weeks on, two weeks off) precludes further dose-intensificatio...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Exp Clin Cancer Res
Huvudupphovsmän: Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Poel, Dennis, Peters, Godefridus J., Griffioen, Arjan W., Verheul, Henk M. W.
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2016
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013589/
https://ncbi.nlm.nih.gov/pubmed/27604186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0411-2
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk